0
Il n'y a pas de produit dans le panier !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Accueil > IL-27

IL-27

Brief Information

Name:Interleukin-27
Target Synonym:IL27,Interleukin-27,Interleukin 27,IL-27A,IL-27
Number of Launched Drugs:0
Number of Drugs in Clinical Trials:1
Lastest Research Phase:Phase 2 Clinical

Product ListCompare or Buy

Par statut du produit :
Par catégorie de produit :
Par espèce :
Cat . Non Espèces Description du produit Structure Pureté Caractéristique
IL7-H5254 Human Human IL-27 Protein, Fc Tag, premium grade
IL7-H5254-sds
IL7-M82E4 Mouse Biotinylated Mouse IL-27 Protein, His,Avitag™
IL7-M82E4-sds
ACRO Quality

Part of Bioactivity data

IL7-H5254-SPR
 IL-27 SPR

Human IL-27 Ra Protein, Fc Tag (Cat. No. ILA-H5254) immobilized on CM5 Chip can bind Human IL-27 Protein, Fc Tag, premium grade (Cat. No. IL7-H5254) with an affinity constant of 3.67 nM as determined in a SPR assay (Biacore 8K) (QC tested).

IL7-M82E4-ELISA
 IL-27 ELISA

Immobilized Human IL-27 Ra, Fc Tag (Cat. No. ILA-H5254) at 5 μg/mL (100 μL/well) can bind Biotinylated Mouse IL-27 Protein, His,Avitag (Cat. No. IL7-M82E4) with a linear range of 0.2-4 ng/mL (QC tested).

Synonym Name

p28,IL30,IL-27,IL-27A,IL27p28,Interleukin-27,EBI3

Background

Interleukin-27 (IL-27) is a heterodimeric cytokine belonging to the IL-12 family that is composed of two subunits, Epstein-Barr virus (EBV)-induced gene 3 (EBI3) (also known as IL-27B) and IL27-p28 (known as IL-30). IL-27 is produced by antigen-presenting cells. IL-27 plays an important function in regulating the activity of B and T lymphocytes. The effects of IL-27 are eliciting by its interaction with a specific cell surface receptor complex composed of two proteins known as IL27R and gp130. IL-27 is a cytokine with pro- and anti-inflammatory properties, that can regulate T helper cell development, suppress T-cell proliferation, stimulate cytotoxic T cell activity, induce isotype switching in B-cells, and that has diverse effects on innate immune cells. Among its target cells are CD4 T helper cells which can differentiate in type 1 effector cells (TH1), type 2 effector cells (TH2) and IL17 producing helper T-cells (TH17). It drives rapid clonal expansion of naive but not memory CD4 T-cells. IL-27 reveals to be a potent inhibitor of TH17 cell development and of IL-17 production. IL-27 also antagonizes the effects of some cytokines such as IL6 through direct effects on T cells. Another important role of IL-27 is its antitumor activity and antiangiogenic activity.

Clinical and Translational Updates

Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
Casdozokitug SRF-388 Phase 2 Clinical Surface Oncology Inc Solid tumours; Carcinoma, Renal Cell; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung Details
Casdozokitug SRF-388 Phase 2 Clinical Surface Oncology Inc Solid tumours; Carcinoma, Renal Cell; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung Details

This web search service is supported by Google Inc.

totop

Laisser un message